Companies and Markets
Call us on +44 (0) 203 086 8600
Market Research A to Z | Company Profiles A to Z | RegisterRegister | Contact UsContact Us | Shopping Basket Shopping Basket
+44 (0) 203 086 8600 Call us on

Monoclonal antibodies market dominated by Remicade and Avastin

Industry Sector

Healthcare and Medical

Published

2 January 2013

Author

Matt Bodimeade

Type of News

Market

With the rollout of at least eight new therapeutic monoclonal antibody products and expanded indications for existing products expected, the monoclonal antibodies market has been forecast to increase at a compound annual growth rate (CAGR) 10.6% through to 2015.

Key factors contributing to this market growth include the increasing prevalence of cancer, along with the increasing use of monoclonal antibodies in the development of personalised medicines.

Monoclonal antibodies are monospecific antibodies that are the same because they are made by identical immune cells that are all clones of a unique parent cell, in contrast to polyclonal antibodies which are made from several different immune cells. Monoclonal antibodies have monovalent affinity, in that they bind to the same epitope.

Monoclonal antibody therapy is the use of monoclonal antibodies (or mAb) to specifically bind to target cells or proteins. This may then stimulate the patient's immune system to attack those cells. It is possible to create a mAb specific to almost any extracellular/ cell surface target, and thus there is a large amount of research and development currently being undergone to create monoclonals for numerous serious diseases (such as rheumatoid arthritis, multiple sclerosis and different types of cancers).

The ability to treat complex disorders with lesser side-effects has accelerated growth of the monoclonal antibodies market, but high developmental costs constitute a major barrier for mid-segment market entrants.

Several monoclonal antibodies have become "Blockbusters", with sales exceeding $1 billion, including Remicade (Johnson & Johnson - $ 7.3 billion in 2010), Avastin (Roche - $ 7.0 billion in 2010), Enbrel (Amgen & Pfizer - $ 6.5 billion in 2010), Humira (Abbott Laboratories - $ 6.5 billion in 2010), Rituxan / MabThera (Roche, Genentech & Biogen - $ 6.8 billion in 2010) and Herceptin (Roche - $ 5.8 billion in 2010).

The US is projected to be the largest single market for therapeutic monoclonal antibodies from 2011 to 2016. This particular market was worth nearly $19.8 billion in 2010 and reached $20.1 billion by 2011. By 2016, the market has been forecast to grow to $27.4 billion, a CAGR of 6.4%.

For more information on the monoclonal antibodies market, see the latest research: Monoclonal Antibodies Market

Follow us on Twitter @CandMResearch

Visitor Comments

All posts are pre-moderated and must obey the house rules.

Change Currency

GBP
USD

Change Currency

GBP
USD

Use our research skills: Get free support

Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support

December Discounted Prices: Contact us to ask about our special discounts available in December

For the last month in 2014 we are offering discounted prices on a selection of new reports. Please contact us on 00 44 (0) 203 0868600 or via email (click here to email) to ask about prices and special discounts.

Available during December and the run-up to Christmas; Discounted prices on a selection of our reports.

Find all the research at the best prices. Great promotions being offered during December!

We are offering our clients substantial savings on the best research available during December. Please contact us either via emailor by calling our team to discuss your specific research needs on Tel: 00 44 (0) 203 0868600. We look forward to being able to find you the research you require at good prices.

Accessibility
Close

Contrast settings

Text size settings